QURE Earnings

QURE reported its FY2025Q3 earnings on 2025-11-10, showcasing a revenue of 4.00M against an estimate of 5.00M, resulting in a -28.18% surprise. The EPS was -1.38, surpassing the expected -0.85 by -62.35% . The stock experienced a -5.9% price change on the earnings day and a 9.18% change over the next five days, reflecting market reactions to the results.

Following QURE's FY2025Q3 earnings announcement on 2025-11-10, the stock price moved by -5.90% on the day of the release. Over the subsequent five days, it saw a 9.18% change. Historically, QURE's stock price tends to shift by an average of +14.41% in the 10 days leading up to earnings and -3.28% in the 10 days following, providing insight into potential market.

For 2025/Q4, analysts estimate QURE’s annual revenue to reach 6.00M, while the EPS is projected at -1.00. These estimates reflect recent revisions, with revenue estimates revised Revenue Revise Downward by -0.15% and EPS estimates Revise Downward by -64.15% over the past three months, indicating analyst expectation in the company’s performance.

The correlation between QURE's stock price and earnings forecast revisions shows that positive revisions in revenue or EPS often strengthen the stock’s fundamentals. Over the past three months, revenue estimates for FY2025 were Revise Downward by -0.15%, while EPS estimates moved Revise Downward by -64.15% . This trend suggests that price dips could present buying opportunities for investors.

Based on historical trends, QURE's stock price typically moves by +14.41% in the 10 days before its earnings and -3.28% in the 10 days after. For the upcoming 2025/Q4 earnings, analysts expect an EPS of -1.00 and revenue of 6.00M.

The earnings call shows mixed signals: strong cash position and potential for AMT-130, but increased expenses and uncertain regulatory outcomes. The Q&A reveals robust testing and a motivated community for Huntington's, but concerns about dose toxicity and unclear FDA interactions. The strategic plan indicates optimism for future approvals, but the lack of EMA/MHRA engagement and management's evasiveness on key questions temper expectations. Overall, the neutral sentiment reflects positive long-term prospects but short-term uncertainties.